Cargando…

Physicochemical properties determining drug detection in skin

Chemicals, including some systemically administered xenobiotics and their biotransformations, can be detected noninvasively using skin swabs and untargeted metabolomics analysis. We sought to understand the principal drivers that determine whether a drug taken orally or systemically is likely to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Bittremieux, Wout, Advani, Rohit S., Jarmusch, Alan K., Aguirre, Shaden, Lu, Aileen, Dorrestein, Pieter C., Tsunoda, Shirley M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932847/
https://www.ncbi.nlm.nih.gov/pubmed/34793633
http://dx.doi.org/10.1111/cts.13198
_version_ 1784671522769600512
author Bittremieux, Wout
Advani, Rohit S.
Jarmusch, Alan K.
Aguirre, Shaden
Lu, Aileen
Dorrestein, Pieter C.
Tsunoda, Shirley M.
author_facet Bittremieux, Wout
Advani, Rohit S.
Jarmusch, Alan K.
Aguirre, Shaden
Lu, Aileen
Dorrestein, Pieter C.
Tsunoda, Shirley M.
author_sort Bittremieux, Wout
collection PubMed
description Chemicals, including some systemically administered xenobiotics and their biotransformations, can be detected noninvasively using skin swabs and untargeted metabolomics analysis. We sought to understand the principal drivers that determine whether a drug taken orally or systemically is likely to be observed on the epidermis by using a random forest classifier to predict which drugs would be detected on the skin. A variety of molecular descriptors describing calculated properties of drugs, such as measures of volume, electronegativity, bond energy, and electrotopology, were used to train the classifier. The mean area under the receiver operating characteristic curve was 0.71 for predicting drug detection on the epidermis, and the SHapley Additive exPlanations (SHAP) model interpretation technique was used to determine the most relevant molecular descriptors. Based on the analysis of 2561 US Food and Drug Administration (FDA)‐approved drugs, we predict that therapeutic drug classes, such as nervous system drugs, are more likely to be detected on the skin. Detecting drugs and other chemicals noninvasively on the skin using untargeted metabolomics could be a useful clinical advancement in therapeutic drug monitoring, adherence, and health status.
format Online
Article
Text
id pubmed-8932847
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89328472022-03-24 Physicochemical properties determining drug detection in skin Bittremieux, Wout Advani, Rohit S. Jarmusch, Alan K. Aguirre, Shaden Lu, Aileen Dorrestein, Pieter C. Tsunoda, Shirley M. Clin Transl Sci Research Chemicals, including some systemically administered xenobiotics and their biotransformations, can be detected noninvasively using skin swabs and untargeted metabolomics analysis. We sought to understand the principal drivers that determine whether a drug taken orally or systemically is likely to be observed on the epidermis by using a random forest classifier to predict which drugs would be detected on the skin. A variety of molecular descriptors describing calculated properties of drugs, such as measures of volume, electronegativity, bond energy, and electrotopology, were used to train the classifier. The mean area under the receiver operating characteristic curve was 0.71 for predicting drug detection on the epidermis, and the SHapley Additive exPlanations (SHAP) model interpretation technique was used to determine the most relevant molecular descriptors. Based on the analysis of 2561 US Food and Drug Administration (FDA)‐approved drugs, we predict that therapeutic drug classes, such as nervous system drugs, are more likely to be detected on the skin. Detecting drugs and other chemicals noninvasively on the skin using untargeted metabolomics could be a useful clinical advancement in therapeutic drug monitoring, adherence, and health status. John Wiley and Sons Inc. 2021-11-28 2022-03 /pmc/articles/PMC8932847/ /pubmed/34793633 http://dx.doi.org/10.1111/cts.13198 Text en © 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Bittremieux, Wout
Advani, Rohit S.
Jarmusch, Alan K.
Aguirre, Shaden
Lu, Aileen
Dorrestein, Pieter C.
Tsunoda, Shirley M.
Physicochemical properties determining drug detection in skin
title Physicochemical properties determining drug detection in skin
title_full Physicochemical properties determining drug detection in skin
title_fullStr Physicochemical properties determining drug detection in skin
title_full_unstemmed Physicochemical properties determining drug detection in skin
title_short Physicochemical properties determining drug detection in skin
title_sort physicochemical properties determining drug detection in skin
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932847/
https://www.ncbi.nlm.nih.gov/pubmed/34793633
http://dx.doi.org/10.1111/cts.13198
work_keys_str_mv AT bittremieuxwout physicochemicalpropertiesdeterminingdrugdetectioninskin
AT advanirohits physicochemicalpropertiesdeterminingdrugdetectioninskin
AT jarmuschalank physicochemicalpropertiesdeterminingdrugdetectioninskin
AT aguirreshaden physicochemicalpropertiesdeterminingdrugdetectioninskin
AT luaileen physicochemicalpropertiesdeterminingdrugdetectioninskin
AT dorresteinpieterc physicochemicalpropertiesdeterminingdrugdetectioninskin
AT tsunodashirleym physicochemicalpropertiesdeterminingdrugdetectioninskin